Monday, 24 Feb 2020

PsA/SpA

Date Typesort ascending Title Save
08 Jan 2020 Social Systematic literature of biologic Rx of dactylitis & enthesitis in Psoriatic arthritis. 18 trials, 6981 patients showed that TNF inhib & ustekinumab, secukinumab, ixekizumab were 2-3 fold significantly better than PBO at resolution of dactylitis by Wk 24. https://t.co/HlQcw5cXsN
12 Nov 2019 Social RT @DrPetryna: @RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media th…
07 Oct 2016 Social Am I wrong?Otezla warnings overstate risk of depression % wt loss; yet understate diarrhea 9% & D/C for diarrhea <2% https://t.co/UwFi8b6txr
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts… https://t.co/O1xSQ6nafD
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
08 May 2019 Social Long term safety of Secukinumab in PsO, PsA, & AS RCTs ( 96,054 patient-years) - favorable results with low incidence of serious infx (1.4, 1.9, 1.2, /100PYs), Candida (2.2, 1.5, 0.7/100pYs), IBD (0.01, 0.05, and 0.1/100PYs) or MACE (0.3, 0.4, 0.6). No TB. https://t.co/BTbBlOYj8W
19 Oct 2016 Social Postural abnormalities and worse spinal metrics in Ankylosing spondylitis is assoc. w/ significant Balance issues. https://t.co/j9nNwjJSQp
06 Nov 2017 Social RT @japaoli19: Significant reduction in immunosuppression load on uveitis pts with long term ADA use. #ACR17 @RheumNow #1115 https://t.co/…
14 Jun 2018 Social RT @RonanTKavanagh: Although disease may be less severe at baseline in Ps A than in RA patients they fare less well at 3 months compared to…
29 Oct 2018 Social European Commission (EC) has approved a label update for Cosentyx (secukinumab), now allowing up to 300 mg dosing and also includes 24-week Xray data with inhibition of progression of joint damage in PsA https://t.co/S6d4XE75Ov
01 Jun 2015 Social RT @DrPetryna: @RheumNow GS ultrasound helps to dx subclinical Achilles enthesitis in AS. Doppler US helps monitor TNFi response http://t.c…
06 Dec 2016 Social In a clinic of 400 pts w/ PsA or Ank spondylitis, 24% fulfilled classification criteria for both conditions. https://t.co/KNWNOz1weq
06 Sep 2017 Social Psoriasis pruritus seen in >80%; metaanalysis 13 trials shows Anti Il-17, JAK inhib, ADA, apremilast reduce pruritus https://t.co/KXbZxLizD0
07 Nov 2017 Social RT @uptoTate: IBD assoc. w/ more severe SpA. Occurs w/ rate of 0.7/100 patient yrs/ 5 yrs in DESIR cohort. #ACR17 @RheumNow #2512 https://t…
16 Jun 2018 Social RT @DrPetryna: #eular18 @RheumNow ABST sat0354 work productivity&presentism negatively impacted by PsA. Low disease activity and remission…
01 Jan 2019 Social Full text review of psoriatic arthritis for NPs and PAs https://t.co/hlLKLAQ9ZX
26 Jul 2019 Social RT @jrheum: The Assessment of Disease Activity in Psoriatic Arthritis: MDA, VLDA, DAPSA, or Something Else? https://t.co/jmyA5KABzM #diseas…
01 Nov 2019 Social Data on 14 261 PsA patients (from 11 European registries) startin TNFi therapy - shows that half (56%) were in DAS28 remission and 53% were ACR20 responders after 6 months, and 3/4 were still on TNFi at 1 year https://t.co/RIHVjyJ7bn
31 Jan 2017 Social Psoriasis and Psoriatic arthritis pts have a 2 fold increased risk of fracture (including vertebral Fx). https://t.co/kobdkEZGQn